Elicera Therapeutics

Elicera Therapeutics is a Swedish biopharmaceutical company focused on developing cell and gene therapies for immune-based cancer treatment. Its pipeline centers on proprietary oncology programs, including the CAR T-cell candidate ELC-301 and the oncolytic virus candidate ELC-100, supported by the iTANK platform technology.

— Elicera Therapeutics
%
Cell therapy candidates45% Autologous or engineered cell-based cancer therapies developed for clinical testing.
Oncolytic virus candidates25% Virus-based immunotherapy programs designed to attack tumors and stimulate immunity.
Platform technology20% iTANK is a proprietary technology intended to enhance immune activation in cell therapies.
Research and development services10% Internal discovery, translational work, and clinical development activities for pipeline assets.

Elicera does not sell commercial medicines; its direct counterparties are mainly research collaborators, clinical trial...

  • Clinical trial patientsprimary

    Patients enrolled in ELC-301 and ELC-100 studies who receive the investigational therapies.

  • Clinical sites and investigatorsprimary

    Hospitals and research centers that administer trials and generate safety/efficacy data.

  • Potential licensing partnerssecondary

    Biopharma companies that may license or co-develop pipeline assets after proof-of-concept.

  • Public grant providerssecondary

    EU and Swedish funding bodies that support early-stage R&D and clinical work.

Elicera is headquartered in Sweden, with its head office in Uppsala and an office in Gothenburg...

  • •Head office in Uppsala, Sweden
  • •Office in Gothenburg, Sweden
  • •Clinical and R&D operations organized from Sweden
  • •Future commercialization targeted to Europe and other markets
  • •Patent and regulatory exposure spans multiple jurisdictions

Elicera’s strategy is to advance its lead oncology programs through clinical proof-of-concept and build value around...

01
Generate clinical proof-of-conceptshort-term

Clinical data is the main value driver for early-stage oncology assets.

02
Strengthen platform differentiationmedium-term

iTANK is intended to improve immune activation and broaden therapeutic utility.

03
Secure funding and partnershipsshort-term

External capital and collaboration can extend runway and support development.

Elicera faces the typical risks of an early-stage biotech company: clinical failure, regulatory delays, and uncertainty...

critical

Clinical development failure

Pipeline value depends on positive Phase I/IIa and preclinical results.

Scope
ELC-301 and ELC-100 programs
Materiality
high
high

Patent and IP protection risk

The company’s assets rely on enforceable patent coverage in multiple jurisdictions.

Scope
iTANK, ELC-301, ELC-100
Materiality
high
high

Financing and dilution risk

Development-stage biotech typically requires repeated external capital raises.

Scope
Warrants, grants, equity financing
Materiality
high
high

Commercialization and pricing risk

Even approved therapies may face reimbursement pressure and pricing scrutiny.

Scope
CAR T-cell therapies and future oncology launches
Materiality
high
medium

Competitive risk

Large multinational pharma companies can advance competing oncology programs faster.

Scope
B-cell lymphoma and immuno-oncology
Materiality
medium
Research and development expense recognition
Makes earnings highly sensitive to trial activity and development pace
Grant accounting
Can materially change reported results from period to period
Capitalization of intangible assets
Prevents asset buildup from internally generated pipeline spending
Going-concern and financing assumptions
Affects disclosure, valuation, and financial statement presentation

Elicio Therapeutics, Inc.

ELTX · Pharmaceutical Preparations

Aldeyra Therapeutics, Inc.

ALDX · Pharmaceutical Preparations

Egetis Therapeutics

EGTX.ST · Health Care

ELUTIA INC.

ELUT · Biological Products, (No Diagnostic Substances)

CalciMedica, Inc.

CALC · Pharmaceutical Preparations

Aclaris Therapeutics, Inc.

ACRS · Pharmaceutical Preparations

: 11/08/2026